APAC Biotech
Hyderabad, India· Est.
India’s first approved dendritic‑cell cancer vaccine developer.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
India’s first approved dendritic‑cell cancer vaccine developer.
OncologyImmunology
Technology Platform
Autologous dendritic cell vaccines that load patient‑specific tumor antigens to activate cytotoxic T‑cell responses.
Opportunities
Expansion into global markets and additional indications (e.g., glioblastoma, pancreatic cancer) could drive significant revenue growth.
Risk Factors
Manufacturing complexity, stringent regulatory requirements, and competition from other personalized immunotherapy platforms pose key risks.
Competitive Landscape
Differentiates through autologous DC vaccines with low toxicity and cost‑effective production, competing with cell‑therapy and mRNA vaccine developers.